{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T16:34:47Z","timestamp":1793896487742,"version":"4.8.0"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,16]],"date-time":"2025-08-16T00:00:00Z","timestamp":1755302400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,16]],"date-time":"2025-08-16T00:00:00Z","timestamp":1755302400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-025-01346-1","type":"journal-article","created":{"date-parts":[[2025,8,16]],"date-time":"2025-08-16T16:10:52Z","timestamp":1755360652000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Newly diagnosed acute myeloid leukemia in unfit patients: 2026 treatment algorithms"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9104-6172","authenticated-orcid":false,"given":"Naseema","family":"Gangat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9003-0390","authenticated-orcid":false,"given":"Courtney D.","family":"Dinardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,16]]},"reference":[{"key":"1346_CR1","unstructured":"https:\/\/seer.cancer.gov\/statfacts\/html\/amyl.html [Internet]."},{"key":"1346_CR2","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, et al. Azacitidine and venetoclax in previously untreated acute myeloid Leukemia. N. Engl J Med. 2020;383:617\u201329.","journal-title":"N. Engl J Med"},{"key":"1346_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00668-8","volume":"12","author":"KW Pratz","year":"2022","unstructured":"Pratz KW, Panayiotidis P, Recher C, Wei X, Jonas BA, Montesinos P, et al. Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia. Blood Cancer J. 2022;12:71.","journal-title":"Blood Cancer J"},{"key":"1346_CR4","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1002\/ajh.27625","volume":"100","author":"S Shimony","year":"2025","unstructured":"Shimony S, Stahl M, Stone RM. Acute Myeloid Leukemia: 2025 Update on diagnosis, risk-stratification, and management. Am J Hematol. 2025;100:860\u201391.","journal-title":"Am J Hematol"},{"key":"1346_CR5","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1182\/bloodadvances.2024013744","volume":"9","author":"A Venditti","year":"2025","unstructured":"Venditti A, Palmieri R, Maurillo L, R\u00f6llig C, Wierzbowska A, de Leeuw D, et al. Fitness assessment in acute myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood Adv. 2025;9:2207\u201320.","journal-title":"Blood Adv"},{"key":"1346_CR6","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1001\/jamaoncol.2017.2714","volume":"3","author":"ML Sorror","year":"2017","unstructured":"Sorror ML, Storer BE, Fathi AT, Gerds AT, Medeiros BC, Shami P, et al. Development and validation of a novel acute myeloid leukemia-composite model to estimate risks of mortality. JAMA Oncol. 2017;3:1675\u201382.","journal-title":"JAMA Oncol"},{"key":"1346_CR7","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1038\/leu.2012.303","volume":"27","author":"F Ferrara","year":"2013","unstructured":"Ferrara F, Barosi G, Venditti A, Angelucci E, Gobbi M, Pane F, et al. Consensus-based definition of unfitness to intensive and non-intensive chemotherapy in acute myeloid leukemia: a project of SIE, SIES and GITMO group on a new tool for therapy decision making. Leukemia. 2013;27:997\u20139.","journal-title":"Leukemia"},{"key":"1346_CR8","doi-asserted-by":"publisher","first-page":"4163","DOI":"10.1200\/JCO.20.01392","volume":"38","author":"R Palmieri","year":"2020","unstructured":"Palmieri R, Othus M, Halpern AB, Percival MM, Godwin CD, Becker PS, et al. Accuracy of SIE\/SIES\/GITMO Consensus Criteria for Unfitness to Predict Early Mortality After Intensive Chemotherapy in Adults With AML or Other High-Grade Myeloid Neoplasm. J Clin Oncol. 2020;38:4163\u201374.","journal-title":"J Clin Oncol"},{"key":"1346_CR9","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1038\/s41409-025-02571-9","volume":"60","author":"MQ Salas","year":"2025","unstructured":"Salas MQ, Salinas-Gonz\u00e1lez R, Guardia L, Solano MT, Padilla C, Moreno C, et al. Frailty assessment and outpatient pre-habilitation for adults undergoing allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2025;60:841\u201350.","journal-title":"Bone Marrow Transplant"},{"key":"1346_CR10","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1182\/blood.2023022611","volume":"143","author":"VR Bhatt","year":"2024","unstructured":"Bhatt VR, Uy GL, Klepin HD. Determining treatment tolerance and fitness for intensive chemotherapy in older adults with AML: a call to action. Blood. 2024;143:483\u20137.","journal-title":"Blood"},{"key":"1346_CR11","doi-asserted-by":"publisher","first-page":"4287","DOI":"10.1182\/blood-2012-12-471680","volume":"121","author":"HD Klepin","year":"2013","unstructured":"Klepin HD, Geiger AM, Tooze JA, Kritchevsky SB, Williamson JD, Pardee TS, et al. Geriatric assessment predicts survival for older adults receiving induction chemotherapy for acute myelogenous leukemia. Blood. 2013;121:4287\u201394.","journal-title":"Blood"},{"key":"1346_CR12","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1002\/ajh.27694","volume":"100","author":"VR Bhatt","year":"2025","unstructured":"Bhatt VR, Wichman CS, Koll TT, Fisher AL, Wildes TM, Haddadin M, et al. A Phase II trial of geriatric assessment-guided selection of treatment intensity in older adults with AML. Am J Hematol. 2025;100:1163\u201372.","journal-title":"Am J Hematol"},{"key":"1346_CR13","doi-asserted-by":"publisher","first-page":"3812","DOI":"10.1182\/bloodadvances.2021006872","volume":"6","author":"EK Ritchie","year":"2022","unstructured":"Ritchie EK, Klepin HD, Storrick E, Major B, Le-Rademacher J, Wadleigh M, et al. Geriatric assessment for older adults receiving less-intensive therapy for acute myeloid leukemia: report of CALGB 361101. Blood Adv. 2022;6:3812\u201320.","journal-title":"Blood Adv"},{"key":"1346_CR14","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345\u201377.","journal-title":"Blood"},{"key":"1346_CR15","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1182\/blood.2024024944","volume":"144","author":"H D\u00f6hner","year":"2024","unstructured":"D\u00f6hner H, Pratz KW, DiNardo CD, Wei AH, Jonas BA, Pullarkat V, et al. Genetic Risk Stratification and Outcomes Among Treatment-Naive Patients With AML Treated With Venetoclax and Azacitidine. Blood. 2024;144:2211\u201322.","journal-title":"Blood"},{"key":"1346_CR16","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1002\/ajh.27138","volume":"99","author":"N Gangat","year":"2024","unstructured":"Gangat N, Karrar O, Iftikhar M, McCullough K, Johnson IM, Abdelmagid M, et al. Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 consecutive patients. Am J Hematol. 2024;99:193\u2013202.","journal-title":"Am J Hematol"},{"key":"1346_CR17","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1182\/blood.2024025409","volume":"144","author":"H D\u00f6hner","year":"2024","unstructured":"D\u00f6hner H, DiNardo CD, Appelbaum F, Craddock C, Dombret H, Ebert BL, et al. Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations. Blood. 2024;144:2169\u201373.","journal-title":"Blood"},{"key":"1346_CR18","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1056\/NEJMoa2117344","volume":"386","author":"P Montesinos","year":"2022","unstructured":"Montesinos P, Recher C, Vives S, Zarzycka E, Wang J, Bertani G, et al. Ivosidenib and Azacitidine in IDH1-mutated acute myeloid leukemia. N Engl J Med. 2022;386:1519\u201331.","journal-title":"N Engl J Med"},{"key":"1346_CR19","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1002\/ajh.27564","volume":"100","author":"N Gangat","year":"2025","unstructured":"Gangat N, Elbeih A, Ghosoun N, McCullough K, Aperna F, Johnson IM, et al. Mayo genetic risk models for newly diagnosed acute myeloid leukemia treated with venetoclax\u2009+\u2009hypomethylating agent. Am J Hematol. 2025;100:260\u201371.","journal-title":"Am J Hematol"},{"key":"1346_CR20","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1200\/JCO.21.01546","volume":"40","author":"KW Pratz","year":"2022","unstructured":"Pratz KW, Jonas BA, Pullarkat V, Recher C, Schuh AC, Thirman MJ, et al. Measurable residual disease response and prognosis in treatment-na\u00efve acute myeloid leukemia with venetoclax and azacitidine. J Clin Oncol. 2022;40:855\u201365.","journal-title":"J Clin Oncol"},{"key":"1346_CR21","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1002\/ajh.27246","volume":"99","author":"KW Pratz","year":"2024","unstructured":"Pratz KW, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, D\u00f6hner H, et al. Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia. Am J Hematol. 2024;99:615\u201324.","journal-title":"Am J Hematol"},{"key":"1346_CR22","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1182\/blood.2019004583","volume":"136","author":"C R\u00f6llig","year":"2020","unstructured":"R\u00f6llig C, Kramer M, Schliemann C, Mikesch J-H, Steffen B, Kr\u00e4mer A, et al. Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia? Blood. 2020;136:823\u201330.","journal-title":"Blood"},{"key":"1346_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01033-7","volume":"14","author":"K Hemminki","year":"2024","unstructured":"Hemminki K, Zitricky F, F\u00f6rsti A, Kontro M, Gjertsen BT, Severinsen MT, et al. Age-specific survival in acute myeloid leukemia in the Nordic countries through a half century. Blood Cancer J. 2024;14:44.","journal-title":"Blood Cancer J"},{"key":"1346_CR24","doi-asserted-by":"publisher","first-page":"100016","DOI":"10.1016\/j.bneo.2024.100016","volume":"1","author":"E Madarang","year":"2024","unstructured":"Madarang E, Lykon J, Zhao W, Sekeres MA, Bradley T, Chandhok NS, et al. Venetoclax and hypomethylating agents in octogenarians and nonagenarians with acute myeloid leukemia. Blood Neoplasia. 2024;1:100016.","journal-title":"Blood Neoplasia"},{"key":"1346_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01000-2","volume":"14","author":"T Badar","year":"2024","unstructured":"Badar T, Nanaa A, Atallah E, Shallis RM, Guilherme SdCC, Goldberg AD, et al. Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND). Blood Cancer J. 2024;14:32.","journal-title":"Blood Cancer J"},{"key":"1346_CR26","doi-asserted-by":"publisher","first-page":"2544","DOI":"10.1038\/s41375-024-02417-1","volume":"38","author":"SA Patel","year":"2024","unstructured":"Patel SA. Managing the unmanageable: evidence-driven approaches to real-world patient prototypes of TP53-mutant myelodysplastic neoplasms and acute myeloid leukemia. Leukemia. 2024;38:2544\u201351.","journal-title":"Leukemia"},{"key":"1346_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00672-y","volume":"12","author":"N Gangat","year":"2022","unstructured":"Gangat N, Tefferi A. To live is well but to live well is better: Venetoclax combination therapy and quality-of-life in acute myeloid leukemia. Blood Cancer J. 2022;12:75.","journal-title":"Blood Cancer J"},{"key":"1346_CR28","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1002\/ajh.27515","volume":"100","author":"CD DiNardo","year":"2025","unstructured":"DiNardo CD, Pratz KW, Panayiotidis P, Wei X, Vorobyev V, Ill\u00e9s \u00c1, et al. The impact of post-remission granulocyte colony-stimulating factor use in the phase 3 studies of venetoclax combination treatments in patients with newly diagnosed acute myeloid leukemia. Am J Hematol. 2025;100:185\u20138.","journal-title":"Am J Hematol"},{"key":"1346_CR29","doi-asserted-by":"publisher","first-page":"2501","DOI":"10.3324\/haematol.2022.281214","volume":"107","author":"N Gangat","year":"2022","unstructured":"Gangat N, Johnson I, McCullough K, Farrukh F, Al-Kali A, Alkhateeb H, et al. Molecular predictors of response to venetoclax plus hypomethylating agent in treatment-naive acute myeloid leukemia. Haematologica. 2022;107:2501\u20135.","journal-title":"Haematologica"},{"key":"1346_CR30","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/S1470-2045(18)30010-X","volume":"19","author":"CD DiNardo","year":"2018","unstructured":"DiNardo CD, Pratz KW, Letai A, Jonas BA, Wei AH, Thirman M, et al. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. Lancet Oncol. 2018;19:216\u201328.","journal-title":"Lancet Oncol"},{"key":"1346_CR31","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","volume":"133","author":"CD DiNardo","year":"2019","unstructured":"DiNardo CD, Pratz K, Pullarkat V, Jonas BA, Arellano M, Becker PS, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133:7\u201317.","journal-title":"Blood"},{"key":"1346_CR32","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1182\/blood.2019003988","volume":"135","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Tiong IS, Quaglieri A, MacRaild S, Loghavi S, Brown FC, et al. Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. Blood. 2020;135:791\u2013803.","journal-title":"Blood"},{"key":"1346_CR33","doi-asserted-by":"publisher","first-page":"3170","DOI":"10.3324\/haematol.2022.282677","volume":"108","author":"N Gangat","year":"2023","unstructured":"Gangat N, Ilyas R, Johnson IM, McCullough K, Al-Kali A, Alkhateeb HB, et al. Outcome of patients with acute myeloid leukemia following failure of frontline venetoclax plus hypomethylating agent therapy. Haematologica. 2023;108:3170\u20134.","journal-title":"Haematologica"},{"key":"1346_CR34","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1182\/bloodadvances.2023011757","volume":"8","author":"A Bataller","year":"2024","unstructured":"Bataller A, Bazinet A, DiNardo CD, Maiti A, Borthakur G, Daver NG, et al. Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax. Blood Adv. 2024;8:927\u201335.","journal-title":"Blood Adv"},{"key":"1346_CR35","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1002\/ajh.25978","volume":"95","author":"E Morsia","year":"2020","unstructured":"Morsia E, McCullough K, Joshi M, Cook J, Alkhateeb HB, Al-Kali A, et al. Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients. Am J Hematol. 2020;95:1511\u201321.","journal-title":"Am J Hematol"},{"key":"1346_CR36","doi-asserted-by":"publisher","first-page":"2501","DOI":"10.3324\/haematol.2022.281214","volume":"107","author":"N Gangat","year":"2022","unstructured":"Gangat N, Johnson I, McCullough K, Farrukh F, Al-Kali A, Alkhateeb H, et al. Molecular predictors of response to venetoclax plus hypomethylating agent in treatment-na\u00efve acute myeloid leukemia. Haematologica. 2022;107:2501\u20135.","journal-title":"Haematologica"},{"key":"1346_CR37","doi-asserted-by":"publisher","first-page":"E416","DOI":"10.1002\/ajh.26692","volume":"97","author":"KW Pratz","year":"2022","unstructured":"Pratz KW, DiNardo CD, Selleslag D, Li J, Yamamoto K, Konopleva M, et al. Postremission cytopenia management in patients with acute myeloid leukemia treated with venetoclax and azacitidine in VIALE-A. Am J Hematol. 2022;97:E416\u2013e9.","journal-title":"Am J Hematol"},{"key":"1346_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-025-01270-4","volume":"15","author":"N Gangat","year":"2025","unstructured":"Gangat N, Tefferi A. Venetoclax schedule in AML: 7 vs 14 vs 21 vs 28 days. Blood Cancer J. 2025;15:56.","journal-title":"Blood Cancer J"},{"key":"1346_CR39","doi-asserted-by":"publisher","first-page":"E63","DOI":"10.1002\/ajh.27180","volume":"99","author":"O Karrar","year":"2024","unstructured":"Karrar O, Abdelmagid M, Rana M, Iftikhar M, McCullough K, Al-Kali A, et al. Venetoclax duration (14 vs. 21 vs. 28\u2009days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia: Comparative analysis of response, toxicity, and survival. Am J Hematol. 2024;99:E63\u2013E6.","journal-title":"Am J Hematol"},{"key":"1346_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-025-01269-x","volume":"15","author":"C Willekens","year":"2025","unstructured":"Willekens C, Bazinet A, Chraibi S, Bataller A, Decroocq J, Arani N, et al. Reduced venetoclax exposure to 7 days vs standard exposure with hypomethylating agents in newly diagnosed AML patients. Blood Cancer J. 2025;15:68.","journal-title":"Blood Cancer J"},{"key":"1346_CR41","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1002\/ajh.27417","volume":"99","author":"S Garciaz","year":"2024","unstructured":"Garciaz S, Dumas P-Y, Bertoli S, Sallman DA, Decroocq J, Belhabri A, et al. Outcomes of acute myeloid leukemia patients who responded to venetoclax and azacitidine and stopped treatment. Am J Hematol. 2024;99:1870\u20136.","journal-title":"Am J Hematol"},{"key":"1346_CR42","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.3390\/cancers14082025","volume":"14","author":"S Garciaz","year":"2022","unstructured":"Garciaz S, Hospital MA, Alary AS, Saillard C, Hicheri Y, Mohty B, et al. Azacitidine plus venetoclax for the treatment of relapsed and newly diagnosed acute myeloid leukemia patients. Cancers. 2022;14:2025.","journal-title":"Cancers"},{"key":"1346_CR43","doi-asserted-by":"publisher","first-page":"3879","DOI":"10.1182\/bloodadvances.2022007083","volume":"6","author":"CC Chua","year":"2022","unstructured":"Chua CC, Hammond D, Kent A, Tiong IS, Konopleva MY, Pollyea DA, et al. Treatment-free remission after ceasing venetoclax-based therapy in patients with acute myeloid leukemia. Blood Adv. 2022;6:3879\u201383.","journal-title":"Blood Adv"},{"key":"1346_CR44","doi-asserted-by":"publisher","first-page":"e18523","DOI":"10.1200\/JCO.2025.43.16_suppl.e18523","volume":"43","author":"I Johnson","year":"2025","unstructured":"Johnson I, Elbeih A, Ghosoun N, McCullough K, Al-Kali A, Alkhateeb HB, et al. Predictors of post-transplant survival in patients with newly diagnosed acute myeloid leukemia receiving frontline venetoclax and hypomethylating agents. J Clin Oncol. 2025;43:e18523\u2013e.","journal-title":"J Clin Oncol"},{"key":"1346_CR45","doi-asserted-by":"publisher","first-page":"694.e1","DOI":"10.1016\/j.jtct.2022.07.022","volume":"28","author":"AC Winters","year":"2022","unstructured":"Winters AC, Bosma G, Abbott D, Minhajuddin M, Jordan C, Pollyea DA, et al. Outcomes are similar after allogeneic hematopoietic stem cell transplant for newly diagnosed acute myeloid leukemia patients who received venetoclax + azacitidine versus intensive chemotherapy. Transpl Cell Ther. 2022;28:694.e1\u2013.e9.","journal-title":"Transpl Cell Ther"},{"key":"1346_CR46","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/s41409-021-01476-7","volume":"57","author":"DA Pollyea","year":"2022","unstructured":"Pollyea DA, Winters A, McMahon C, Schwartz M, Jordan CT, Rabinovitch R, et al. Venetoclax and azacitidine followed by allogeneic transplant results in excellent outcomes and may improve outcomes versus maintenance therapy among newly diagnosed AML patients older than 60. Bone Marrow Transpl. 2022;57:160\u20136.","journal-title":"Bone Marrow Transpl"},{"key":"1346_CR47","doi-asserted-by":"publisher","first-page":"e68978fe","DOI":"10.1097\/01.HS9.0000969008.68978.fe","volume":"7","author":"K Pratz","year":"2023","unstructured":"Pratz K, Dinardo C, L Arellano M, Thirman M, Pullarkat V, S. Becker P, et al. P525: Long-term outcomes of stem cell transplant in older patients with acute myeloid leukemia treated with venetoclax + HMA therapies. HemaSphere. 2023;7:e68978fe.","journal-title":"HemaSphere"},{"key":"1346_CR48","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41375-018-0357-9","volume":"33","author":"N Daver","year":"2019","unstructured":"Daver N, Schlenk RF, Russell NH, Levis MJ. Targeting FLT3 mutations in AML: review of current knowledge and evidence. Leukemia. 2019;33:299\u2013312.","journal-title":"Leukemia"},{"key":"1346_CR49","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1056\/NEJMoa1614359","volume":"377","author":"RM Stone","year":"2017","unstructured":"Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD, et al. Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation. N. Engl J Med. 2017;377:454\u201364.","journal-title":"N. Engl J Med"},{"key":"1346_CR50","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1016\/S0140-6736(23)00464-6","volume":"401","author":"HP Erba","year":"2023","unstructured":"Erba HP, Montesinos P, Kim HJ, Patkowska E, Vrhovac R, \u017d\u00e1k P, et al. Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;401:1571\u201383.","journal-title":"Lancet"},{"key":"1346_CR51","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","volume":"381","author":"AE Perl","year":"2019","unstructured":"Perl AE, Martinelli G, Cortes JE, Neubauer A, Berman E, Paolini S, et al. Gilteritinib or chemotherapy for relapsed or refractory FLT3-Mutated AML. N Engl J Med. 2019;381:1728\u201340.","journal-title":"N Engl J Med"},{"key":"1346_CR52","doi-asserted-by":"publisher","first-page":"4655","DOI":"10.1182\/blood-2013-01-480228","volume":"121","author":"F Ravandi","year":"2013","unstructured":"Ravandi F, Alattar ML, Grunwald MR, Rudek MA, Rajkhowa T, Richie MA, et al. Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. Blood. 2013;121:4655\u201362.","journal-title":"Blood"},{"key":"1346_CR53","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1002\/ajh.25198","volume":"93","author":"M Ohanian","year":"2018","unstructured":"Ohanian M, Garcia-Manero G, Levis M, Jabbour E, Daver N, Borthakur G, et al. Sorafenib combined with 5-azacytidine in older patients with untreated FLT3-ITD mutated acute myeloid leukemia. Am J Hematol. 2018;93:1136\u201341.","journal-title":"Am J Hematol"},{"key":"1346_CR54","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1182\/blood.2021014586","volume":"140","author":"ES Wang","year":"2022","unstructured":"Wang ES, Montesinos P, Minden MD, Lee J-H, Heuser M, Naoe T, et al. Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapy. Blood. 2022;140:1845\u201357.","journal-title":"Blood"},{"key":"1346_CR55","doi-asserted-by":"publisher","first-page":"2744","DOI":"10.1158\/1078-0432.CCR-21-3405","volume":"28","author":"M Konopleva","year":"2022","unstructured":"Konopleva M, Thirman MJ, Pratz KW, Garcia JS, Recher C, Pullarkat V, et al. Impact of FLT3 Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Na\u00efve Acute Myeloid Leukemia. Clin Cancer Res. 2022;28:2744\u201352.","journal-title":"Clin Cancer Res"},{"key":"1346_CR56","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.3324\/haematol.2019.244020","volume":"106","author":"R Singh Mali","year":"2021","unstructured":"Singh Mali R, Zhang Q, DeFilippis RA, Cavazos A, Kuruvilla VM, Raman J, et al. Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia models. Haematologica. 2021;106:1034\u201346.","journal-title":"Haematologica"},{"key":"1346_CR57","doi-asserted-by":"publisher","first-page":"4048","DOI":"10.1200\/JCO.22.00602","volume":"40","author":"N Daver","year":"2022","unstructured":"Daver N, Perl AE, Maly J, Levis M, Ritchie E, Litzow M, et al. Venetoclax plus gilteritinib for FLT3-mutated relapsed\/refractory acute myeloid leukemia. J Clin Oncol. 2022;40:4048\u201359.","journal-title":"J Clin Oncol"},{"key":"1346_CR58","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1200\/JCO.23.01911","volume":"42","author":"NJ Short","year":"2024","unstructured":"Short NJ, Daver N, Dinardo CD, Kadia T, Nasr LF, Macaron W, et al. Azacitidine, venetoclax, and gilteritinib in newly diagnosed and relapsed or refractory FLT3-Mutated AML. J Clin Oncol. 2024;42:1499\u20131508.","journal-title":"J Clin Oncol"},{"key":"1346_CR59","doi-asserted-by":"crossref","unstructured":"Yilmaz M MM, Short N, Loghavi S, Kadia T, DiNardo C, et al. PHASE I\/II Study of decitabine, venetoclax, and quizartinib triplet combination in FLT3-ITD mutated AML. HemaSphere. 2025;9.","DOI":"10.1182\/blood-2024-204296"},{"key":"1346_CR60","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00497-1","volume":"11","author":"GC Issa","year":"2021","unstructured":"Issa GC, DiNardo CD. Acute myeloid leukemia with IDH1 and IDH2 mutations: 2021 treatment algorithm. Blood Cancer J. 2021;11:107.","journal-title":"Blood Cancer J"},{"key":"1346_CR61","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1182\/blood.2019002140","volume":"135","author":"GJ Roboz","year":"2020","unstructured":"Roboz GJ, DiNardo CD, Stein EM, de Botton S, Mims AS, Prince GT, et al. Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia. Blood. 2020;135:463\u201371.","journal-title":"Blood"},{"key":"1346_CR62","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1200\/JCO.20.01632","volume":"39","author":"CD DiNardo","year":"2021","unstructured":"DiNardo CD, Stein AS, Stein EM, Fathi AT, Frankfurt O, Schuh AC, et al. Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia. J Clin Oncol. 2021;39:57\u201365.","journal-title":"J Clin Oncol"},{"key":"1346_CR63","doi-asserted-by":"publisher","first-page":"2575","DOI":"10.1038\/s41375-019-0472-2","volume":"33","author":"DA Pollyea","year":"2019","unstructured":"Pollyea DA, Tallman MS, de Botton S, Kantarjian HM, Collins R, Stein AS, et al. Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia. Leukemia. 2019;33:2575\u201384.","journal-title":"Leukemia"},{"key":"1346_CR64","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1016\/S1470-2045(21)00494-0","volume":"22","author":"CD DiNardo","year":"2021","unstructured":"DiNardo CD, Schuh AC, Stein EM, Montesinos P, Wei AH, de Botton S, et al. Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial. Lancet Oncol. 2021;22:1597\u2013608.","journal-title":"Lancet Oncol"},{"key":"1346_CR65","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1182\/bloodadvances.2023010563","volume":"8","author":"SF Cai","year":"2024","unstructured":"Cai SF, Huang Y, Lance JR, Mao HC, Dunbar AJ, McNulty SN, et al. A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2-mutant AML. Blood Adv. 2024;8:429\u201340.","journal-title":"Blood Adv"},{"key":"1346_CR66","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1158\/1078-0432.CCR-21-3467","volume":"28","author":"DA Pollyea","year":"2022","unstructured":"Pollyea DA, DiNardo CD, Arellano ML, Pigneux A, Fiedler W, Konopleva M, et al. Impact of Venetoclax and Azacitidine in Treatment-Na\u00efve Patients with Acute Myeloid Leukemia and IDH1\/2 Mutations. Clin Cancer Res. 2022;28:2753\u201361.","journal-title":"Clin Cancer Res"},{"key":"1346_CR67","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/nm.3788","volume":"21","author":"SM Chan","year":"2015","unstructured":"Chan SM, Thomas D, Corces-Zimmerman MR, Xavy S, Rastogi S, Hong WJ, et al. Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia. Nat Med. 2015;21:178\u201384.","journal-title":"Nat Med"},{"key":"1346_CR68","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1038\/s41375-021-01468-y","volume":"36","author":"S Cathelin","year":"2022","unstructured":"Cathelin S, Sharon D, Subedi A, Cojocari D, Phillips DC, Leverson JD, et al. Enasidenib-induced differentiation promotes sensitivity to venetoclax in IDH2-mutated acute myeloid leukemia. Leukemia. 2022;36:869\u201372.","journal-title":"Leukemia"},{"key":"1346_CR69","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1158\/2643-3230.BCD-22-0205","volume":"4","author":"CA Lachowiez","year":"2023","unstructured":"Lachowiez CA, Loghavi S, Zeng Z, Tanaka T, Kim YJ, Uryu H, et al. A Phase Ib\/II Study of Ivosidenib with Venetoclax \u00b1 Azacitidine in IDH1-Mutated Myeloid Malignancies. Blood Cancer Discov. 2023;4:276\u201393.","journal-title":"Blood Cancer Discov"},{"key":"1346_CR70","doi-asserted-by":"publisher","unstructured":"DiNardo CD, Marvin-Peek J, Loghavi S, Takahashi K, Issa GC, Jen WY, et al. Outcomes of Frontline Triplet Regimens With a Hypomethylating Agent, Venetoclax, and Isocitrate Dehydrogenase Inhibitor for Intensive Chemotherapy-Ineligible Patients With Isocitrate Dehydrogenase-Mutated AML. J Clin Oncol. 2025:Jco2500640. https:\/\/doi.org\/10.1200\/JCO-25-00640.","DOI":"10.1200\/JCO-25-00640"},{"key":"1346_CR71","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00557-6","volume":"11","author":"GC Issa","year":"2021","unstructured":"Issa GC, Zarka J, Sasaki K, Qiao W, Pak D, Ning J, et al. Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements. Blood Cancer J. 2021;11:162.","journal-title":"Blood Cancer J"},{"key":"1346_CR72","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1200\/JCO.24.00826","volume":"43","author":"GC Issa","year":"2025","unstructured":"Issa GC, Aldoss I, Thirman MJ, DiPersio J, Arellano M, Blachly JS, et al. Menin inhibition with revumenib for KMT2A-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101). J Clin Oncol. 2025;43:75\u201384.","journal-title":"J Clin Oncol"},{"key":"1346_CR73","doi-asserted-by":"publisher","unstructured":"Zeidner JF, Lin TL, Welkie RL, Curran E, Koenig K, Stock W, et al. Azacitidine, venetoclax, and revumenib for newly diagnosed NPM1-Mutated or KMT2A-Rearranged AML. J Clin Oncol. 2025:Jco2500914. https:\/\/doi.org\/10.1200\/JCO-25-00914.","DOI":"10.1200\/JCO-25-00914"},{"key":"1346_CR74","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1038\/s41586-023-05812-3","volume":"615","author":"GC Issa","year":"2023","unstructured":"Issa GC, Aldoss I, DiPersio J, Cuglievan B, Stone R, Arellano M, et al. The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia. Nature. 2023;615:920\u20134.","journal-title":"Nature"},{"key":"1346_CR75","doi-asserted-by":"publisher","first-page":"e56956b1","DOI":"10.1097\/01.HS9.0000974364.56956.b1","volume":"7","author":"AM Zeidan","year":"2023","unstructured":"Zeidan AM, Fathi A, Issa G, Erba H, Mackey JA, Corum D, et al. Pb1885: Phase 1 Study of Ziftomenib in Combination with Venetoclax, Venetoclax\/Azacitidine, or Standard Induction (7\u2009+\u20093) Chemotherapy in Patients with Acute Myeloid Leukemia. Hemasphere. 2023;7:e56956b1 https:\/\/doi.org\/10.1097\/01.HS9.0000974364.56956.b1.","journal-title":"Hemasphere"},{"key":"1346_CR76","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1016\/S1470-2045(24)00386-3","volume":"25","author":"ES Wang","year":"2024","unstructured":"Wang ES, Issa GC, Erba HP, Altman JK, Montesinos P, DeBotton S, et al. Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial. Lancet Oncol. 2024;25:1310\u201324.","journal-title":"Lancet Oncol"},{"key":"1346_CR77","unstructured":"Wei AH RJ, Garciaz S, Aldoss I, Pierola AA, Allred A, et al. RP2D Determination of bleximenib in combination with VEN+AZA: phase 1B study in ND & R\/R AML with KMT2A\/NPM1 alterations. HemaSphere. 2025;9."},{"key":"1346_CR78","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1182\/blood-2024-204375","volume":"144","author":"GC Issa","year":"2024","unstructured":"Issa GC, Cuglievan B, Daver N, DiNardo CD, Farhat A, Short NJ, et al. Phase I\/II Study of the All-Oral Combination of Revumenib (SNDX-5613) with Decitabine\/Cedazuridine (ASTX727) and Venetoclax (SAVE) in R\/R AML. Blood. 2024;144:216.","journal-title":"Blood"},{"key":"1346_CR79","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1080\/10428194.2023.2224473","volume":"64","author":"SA Patel","year":"2023","unstructured":"Patel SA. Precision and strategic targeting of novel mutation-specific vulnerabilities in acute myeloid leukemia: the semi-centennial of 7\u2009+\u20093. Leuk Lymphoma. 2023;64:1503\u201313.","journal-title":"Leuk Lymphoma"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01346-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01346-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01346-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T15:08:57Z","timestamp":1757430537000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01346-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,16]]},"references-count":79,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1346"],"URL":"https:\/\/doi.org\/10.1038\/s41408-025-01346-1","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,16]]},"assertion":[{"value":"27 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"NG has served on the Advisory Board for Agios and DISC Medicine. CDD: Consultant\/Advisory Boards: Abbvie, AstraZeneca, Astellas, BMS, Genentech, GenMab, GSK, Notable Labs, Rigel, Ryvu, Schrodinger, Servier. CDD is supported by the LLS Scholar in Clinical Research Award.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"139"}}